Title |
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma
|
---|---|
Published in |
BMC Veterinary Research, November 2016
|
DOI | 10.1186/s12917-016-0882-6 |
Pubmed ID | |
Authors |
Sarah B. Rippy, Heather L. Gardner, Sandra M. Nguyen, Emma E. Warry, Roberta F. Portela, William Tod Drost, Eric T. Hostnik, Eric M. Green, Dennis J. Chew, Juan Peng, Cheryl A. London |
Abstract |
Effective therapies for transitional cell carcinoma (TCC) are limited, with objective response rates to most chemotherapeutic regimens below 20%. The purpose of this study was to investigate the biologic activity of combined toceranib phosphate and vinblastine chemotherapy for treatment of TCC. A secondary objective was to compare the utility of Computed Tomography (CT) and abdominal ultrasound (AUS) in tumor response assessments. Dogs with TCC received vinblastine at 1.6 mg/m2 every 2 weeks and toceranib at 2.5-2.75 mg/kg on Monday/Wednesday/Friday. Tumor monitoring was achieved through CT and AUS. Five patients completed the 16-week study. Based on AUS assessments, 3 dogs experienced biologic response to therapy including partial responses (PR, n = 2) and stable disease (SD, n = 1). Based on CT, 5 dogs experienced a biologic response (n = 2 PR, n = 3 SD). Both imaging modalities (ultrasound and CT) were found to provide repeatable measurements between operators, however agreement between operator measurements was greater when CT images were used to assess tumor size. The combination of toceranib and vinblastine did not result in improved response rates. While agreement in tumor volume assessments between both AUS and CT were excellent between operators, this did not extend to assessment of tumor response. The higher rate of concordance between operators when assessing response to treatment with CT suggests that CT should be considered for future clinical trials involving canine bladder TCC to improve the accuracy and repeatability of tumor measurement. The data suggest that response to therapy as assessed by AUS or CT do not predict duration of clinical response. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 99 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 18 | 18% |
Student > Master | 15 | 15% |
Researcher | 12 | 12% |
Student > Postgraduate | 11 | 11% |
Student > Doctoral Student | 5 | 5% |
Other | 17 | 17% |
Unknown | 21 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Veterinary Science and Veterinary Medicine | 50 | 51% |
Medicine and Dentistry | 8 | 8% |
Agricultural and Biological Sciences | 7 | 7% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Business, Management and Accounting | 1 | 1% |
Other | 2 | 2% |
Unknown | 28 | 28% |